(Q33720948)

28 July 2017

1 reference

title

Selective cyclooxygenase-2 inhibitors for the treatment of arthritis (English)

1 reference

28 July 2017

Fung HB

1

1 reference

28 July 2017

Kirschenbaum HL

series ordinal

2

1 reference

28 July 2017

publication date

1 July 1999

1 reference

28 July 2017

published in

Clinical Therapeutics

1 reference

28 July 2017

volume

21

1 reference

28 July 2017

issue

7

1 reference

28 July 2017

page(s)

1131-1157

1 reference

Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Guidelines for the medical management of osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Clinical presentation of peptic ulcer in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

The clinical implications of inhibition of the inducible form of cyclo-oxygenase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

New insights into the mode of action of anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Mechanism of action of nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Safety of meloxicam: a global analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980018-1

7 January 2021

10.1016/S0149-2918(00)80018-1

Identifiers

DOI

1 reference

28 July 2017

1 reference